Boston?The 12-month results of two randomized clinical trials of ranibizumab (Lucentis, Genentech) indicate that the drug shows encouraging signs of activity against vascular endothelial growth factor (VEGF) in age-related macular degeneration (AMD).
An investigational ophthalmic combination product containing tobramycin 0.3% and prednisolone acetate 1% seems to be bioequivalent to a marketed preparation of prednisolone acetate 1%, according to recently released results from a phase III trial.
During resident clinic recently, I met an elderly woman suffering from age-related macular degeneration (AMD). Upset with 20/300 vision in her left eye, she was desperate to maintain her right eye's 20/25 vision.
South San Francisco, CA?Genentech Inc.'s ranibizumab (Lucentis), a much-anticipated potential treatment for wet age-related macular degeneration (AMD), has received priority review status from the FDA as part of its Biologics License Application filing.
Fort Worth, TX?The European Medicines Agency's Committee for Medicinal Products for Human Use has reacted positively to the initial marketing authorization for Alcon Laboratories' travoprost 0.004%/ timolol 0.5% solution (DuoTrav) for lowering IOP.
Madison, WI?Investigators expanded the eligibility criteria of the SCORE study, a multicenter, randomized clinical trial designed to investigate the safety and efficacy of standard care versus intravitreal triamcinolone acetonide (IVTA) injections for the treatment of macular edema associated with central and branch retinal vein occlusion. The broader standards will accommodate a patient population more closely matched to those seen in the practice setting.
Carlsbad, CA?SynergEyes Inc. has launched its interactive Web site at www.synergeyes.com. The site offers the ophthalmic industry and the general public the opportunity to obtain product information for the hybrid contact lenses produced by the company. SynergEyes lenses feature a rigid, gas-permeable center and a soft, hydrophilic outer skirt, resulting in a durable hybrid lens for patients seeking crisp, clear vision with the comfort of a soft lens.
Chicago?Evidence of a rising incidence of acute endophthalmitis postcataract surgery has intensified attention regarding the role of antibiotic prophylaxis, but the jury is still out on the efficacy of topical and intracameral therapy for reducing the risk of this sight-threatening infection, said Robert W. Snyder, MD, PhD, at the American Academy of Ophthalmology annual meeting.